IGF‐1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER‐positive breast cancer
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
IGF‐1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER‐positive breast cancer
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF CANCER
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-09-06
DOI
10.1002/ijc.32668
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Hierarchical clustering of activated proteins in the PI3K and MAPK pathways in ER-positive, HER2-negative breast cancer with potential therapeutic consequences
- (2018) Dinja T. Kruger et al. BRITISH JOURNAL OF CANCER
- 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
- (2017) Hongchao Pan et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Phosphoinositide-3-Kinase-Akt-mTOR Pathway as a Therapeutic Target in Breast Cancer
- (2017) Josh Lauring et al. Journal of the National Comprehensive Cancer Network
- Endocrine treatment in breast cancer: Cure, resistance and beyond
- (2016) Konstantinos Tryfonidis et al. CANCER TREATMENT REVIEWS
- Translational Medicine Guide transforms drug development processes: the recent Merck experience
- (2016) Hugues Dolgos et al. DRUG DISCOVERY TODAY
- Endocrine resistance in hormone-responsive breast cancer: mechanisms and therapeutic strategies
- (2016) Conleth G Murphy et al. ENDOCRINE-RELATED CANCER
- A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer
- (2016) Alberto A. Chiappori et al. ONCOLOGIST
- Combined and individual tumor-specific expression of insulin-like growth factor-I receptor, insulin receptor and phospho-insulin-like growth factor-I receptor/insulin receptor in primary breast cancer: Implications for prognosis in different treatment groups
- (2016) Sofie Björner et al. Oncotarget
- Insulin, insulin receptors, and cancer
- (2016) R. Vigneri et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials
- (2015) LANCET
- Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study
- (2015) Martin Fassnacht et al. LANCET ONCOLOGY
- The impact of IGF-1R expression on the outcomes of patients with breast cancer: a meta-analysis
- (2015) Shunchao Yan et al. OncoTargets and Therapy
- Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update
- (2014) Harold J. Burstein et al. JOURNAL OF CLINICAL ONCOLOGY
- Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial
- (2013) John FR Robertson et al. LANCET ONCOLOGY
- Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer
- (2013) Pushpendra Singh et al. MEDICAL ONCOLOGY
- Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit
- (2012) Josefine Bostner et al. BREAST CANCER RESEARCH AND TREATMENT
- Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes
- (2011) Rinat Yerushalmi et al. BREAST CANCER RESEARCH AND TREATMENT
- A Kinome-Wide Screen Identifies the Insulin/IGF-I Receptor Pathway as a Mechanism of Escape from Hormone Dependence in Breast Cancer
- (2011) E. M. Fox et al. CANCER RESEARCH
- Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment
- (2011) S C Drury et al. ENDOCRINE-RELATED CANCER
- Phosphatidylinositol 3-Kinase and Antiestrogen Resistance in Breast Cancer
- (2011) Todd W. Miller et al. JOURNAL OF CLINICAL ONCOLOGY
- The IGF Pathway Regulates ERα through a S6K1-Dependent Mechanism in Breast Cancer Cells
- (2011) Marc A. Becker et al. MOLECULAR ENDOCRINOLOGY
- Divergent effects of insulin-like growth factor-1 receptor expression on prognosis of estrogen receptor positive versus triple negative invasive ductal breast carcinoma
- (2010) Hermien Hartog et al. BREAST CANCER RESEARCH AND TREATMENT
- Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor–positive human breast cancer
- (2010) Todd W. Miller et al. JOURNAL OF CLINICAL INVESTIGATION
- Estrogen Receptor-α Phosphorylation at Serine-118 and Tamoxifen Response in Breast Cancer
- (2009) Marleen Kok et al. JNCI-Journal of the National Cancer Institute
- Tamoxifen Resistance in Breast Tumors Is Driven by Growth Factor Receptor Signaling with Repression of Classic Estrogen Receptor Genomic Function
- (2008) S. Massarweh et al. CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now